Brain metastasis from prostate carcinoma

McCutcheon, Ian E.; Eng, David Y.; Logothetis, Christopher J.

doi:10.1002/(sici)1097-0142(19991201)86:11<2301::aid-cncr18>3.0.co;2-d

Cited by 95 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, prognosis is generally poor for patients with CNS metastasis of prostate cancer, with a median survival of 1 month upon diagnosis of CNS involvement and 3.5 months if stereotactic radiotherapy is used. 3 As observed by Salvati and colleagues, this generally is not due to recurrence at the CNS site, rather death is usually a result of progression of additional metastatic disease. 5 This too appears to be the case for our patient as surveillance imaging has already demonstrated likely skeletal progression of disease.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen

Campagna

Feia

2018

Urology Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

“…Of note, while a majority of intraparenchymal metastases are adenocarcinoma in histology due to its >95% prevalence in overall cases of prostate cancer, small cell carcinoma is significantly more likely to produce brain metastasis. 2 , 3 …”

Section: Discussionmentioning

confidence: 99%

Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen

Campagna

Feia

2018

Urology Case Reports

View full text Add to dashboard Cite

“…54 Another feature of SCC of the prostate that distinguishes it from prostatic adenocarcinoma is a greater tendency to metastasize to the brain, often presenting with symptoms related to central nervous system involvement. 58 In general, prostatic SCC is usually suspected on the basis of one or more of the aforementioned presenting features, which should trigger a prompt diagnostic work up.…”

Section: Clinical Featuresmentioning

confidence: 99%

Small cell carcinoma of the prostate

et al. 2014

View full text Add to dashboard Cite

Pure small-cell carcinoma (SCC) of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Histologically, prostatic SCCs of the prostate are part of a spectrum of anaplastic tumours of the prostate and are similar to SCCs of the lungs. In most cases, SCC of the prostate is associated with conventional prostatic adenocarcinoma. Both components of these mixed tumours frequently share molecular alterations such as ERG gene rearrangements or AURKA and MYCN amplifications, suggesting a common clonal origin. The clinical behaviour of small-cell prostate carcinomas is characterized by extensive local disease, visceral disease, and low PSA levels despite large metastatic burden. Commonly, the emergence of the SCC occurs in patients with high-grade adenocarcinoma who are often treated with androgen deprivation treatment (ADT). However, SCCs do not usually benefit from ADT. A biopsy of accessible lesions is strongly recommended to identify those with SCC pathological features, as management is undoubtedly affected by this finding. Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic SCC. Despite the emergence of more-aggressive treatment modalities, the prognosis of men with prostatic SCC remains dismal.

show abstract

“…Cerebral metastases as an early clinical presentation of prostate adenocarcinoma are extremely rare [1,3,5-7]. Various hypothesis have been proposed about the mechanism of intracranial metastasis.…”

Section: Discussionmentioning

confidence: 99%

Solitary Brain Metastasis: A Rare Initial Presentation of Prostate Carcinoma

Hafiz¹,

Karim²,

Qureshi³

et al. 2019

Cureus

View full text Add to dashboard Cite

Cerebral metastasis as an initial clinical presentation of prostate carcinoma is extremely rare. Usually, patients have widespread metastasis in the body before presenting with brain metastasis. In the absence of extensive metastasis, especially without bony metastasis, only brain metastasis is an unusual presentation of the disease. We report a case of a 59-years-old patient who presented with a lack of concentration and decreased vision. Magnetic resonance imaging (MRI) of the brain revealed a large right parietal-occipital space-occupying lesion. He underwent surgery and the pathological diagnosis of the tumor turned out to be metastatic prostate carcinoma. Further evaluation by a whole-body computed tomography (CT) scan revealed an enlarged prostate with no other metastatic deposit and a mildly raised level of prostate-specific antigen (PSA). It was possible for us to provide this patient with multi-modality treatment with the help of multidisciplinary tumor board meetings. Further studies addressing the biological as well as clinical characteristics of prostate carcinoma with this rare metastatic presentation will help us to define prognostic factors and therapeutic intervention and will help us to understand the basis of this unique presentation without bone metastasis.

show abstract

Brain metastasis from prostate carcinoma

Cited by 95 publications

References 55 publications

Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen

Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen

Small cell carcinoma of the prostate

Solitary Brain Metastasis: A Rare Initial Presentation of Prostate Carcinoma

Contact Info

Product

Resources

About